Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Endometriosis Trial: Study of NBI-56418 in Endometriosis

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00109512
First received: April 28, 2005
Last updated: February 21, 2012
Last verified: February 2012

April 28, 2005
February 21, 2012
April 2005
June 2006   (final data collection date for primary outcome measure)
Total Composite Pelvic Signs and Symptom Scale (CPSSS) scores [ Time Frame: Every 4 weeks ] [ Designated as safety issue: No ]
This scale is used to assess the signs (pelvic tenderness and induration) and symptoms (nonmenstrual pelvic pain, dysmenorrhea and dyspareunia) associated with endometriosis.
Not Provided
Complete list of historical versions of study NCT00109512 on ClinicalTrials.gov Archive Site
  • Endometriosis Health Profile-5 (EHP-5) [ Time Frame: Every 4 weeks ] [ Designated as safety issue: No ]
    The EHP-5 assesses quality of life.
  • Visual Analog Scale (VAS) scores [ Time Frame: Every 4 weeks ] [ Designated as safety issue: No ]
    VAS measures endometriosis pain.
  • Number of Subjects with Adverse Events [ Time Frame: Up to 24 weeks ] [ Designated as safety issue: Yes ]
  • Clinical Laboratory Tests [ Time Frame: Up to 24 weeks ] [ Designated as safety issue: Yes ]
  • Vital Sign Measurements [ Time Frame: Up to 24 weeks ] [ Designated as safety issue: Yes ]
  • Physical Examinations [ Time Frame: Up to 24 weeks ] [ Designated as safety issue: Yes ]
  • Electrocardiogram (ECG) tracings [ Time Frame: Up to 24 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
Endometriosis Trial: Study of NBI-56418 in Endometriosis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NBI-56418 in Endometriosis

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with subjects randomized to one of three treatment groups, placebo, 75 mg and 150 mg in a 1:1:1 ratio. Study drug was administered once daily for 12 weeks. After the last dose at the end of Week 12, follow-up continued every 4 weeks for 12 weeks.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Endometriosis
  • Drug: NBI-56418 (GnRH antagonist)
  • Drug: placebo
  • Placebo Comparator: placebo
    Intervention: Drug: placebo
  • Experimental: NBI-56418 75 mg
    Intervention: Drug: NBI-56418 (GnRH antagonist)
  • Experimental: NBI-56418 150 mg
    Intervention: Drug: NBI-56418 (GnRH antagonist)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
76
June 2006
June 2006   (final data collection date for primary outcome measure)

Inclusion Criteria

  • Be female, aged 18 to 49 years, inclusive.
  • Have pelvic pain and dysmenorrhea resulting in a Composite Pelvic Sign and Symptoms Score (CPSSS) of ≥ 6.
  • Have had a diagnosis of endometriosis made following laparoscopic visualization of the disease within the last 5 years of the start of screening.
  • Have regular menstrual cycles (28 days ±5 days) for greater than or equal to 2 years. For the cycle that immediately precedes dosing, cycle length will be determined as part of the medical history.
  • Have a Body Mass Index between 18 and 30 kg/m2.
  • Agree to use two forms of non-hormonal contraception (unless sterilized by tubal ligation) for greater than or equal to 3 months prior to Screening through ovulation and return of menses after treatment.
  • Have a negative serum pregnancy test at Screening and a negative urine pregnancy test at prior to dosing at the beginning of Week 1.
  • Have a cervical smear negative for malignancy at Screening.
  • Be willing to comply with all study procedures and restrictions.
  • Be able to read, understand, and sign the ICF (informed consent form) before entering into the study.
  • Be willing to provide authorization for access to personal health information in conjunction with US Health Insurance Portability and Accountability Act (HIPAA).

Exclusion Criteria

  • Are currently receiving a GnRH agonist or GnRH antagonist, or have received any of these agents within 6 months of Screening.
  • Have been nonresponsive to GnRH agonist or antagonist therapy for the management of endometriosis.
  • Are currently receiving hormonal therapy including the oral contraceptive pill or have received any of these agents within 3 months of Screening.
  • Are on any concurrent medical treatment/medications or have had surgical or hormonal treatment other than oral contraceptives for endometriosis within 3 months of Screening.
  • Have uterine fibroids or any other pelvic lesions greater than or equal to 3 cm in diameter as verified by ultrasound.
  • Are currently breast-feeding an infant.
  • Are using any steroid preparation, taken by any route (e.g., oral, inhaled) on a chronic or regular basis within 3 months of Screening.
  • Have an unstable medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary, or endocrine disease), or malignancy that could confound interpretation of the study outcomes.
  • Have chronic pelvic pain that is not caused by endometriosis.
  • Have any psychological disorder according to criteria indicated in the Diagnostics and Statistical Manual of Mental Disorders, 4th edition within one year before screening. Such disorders include, but are not limited to, alcohol and substance abuse/dependence.
  • Have a history of poor compliance in clinical research studies.
  • Have a medically significant illness in the 30 days before the beginning of Week 1.
  • Have a medically significant abnormality observed upon Screening or the beginning of Week 1 physical examination, or in any other baseline measurement. Findings outside the standard reference ranges will be jointly approved with NBI's (Neurocrine Biosciences) Medical Monitor before being considered eligible for the study.
  • Are using any investigational drug within 2 months of Screening.
  • Have a positive human immunodeficiency virus antibody (HIV Ab), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (HCV-Ab) assay at Screening or have a history of a positive result.
  • Have an allergy, hypersensitivity, or intolerance to a GnRH agonist or antagonist.
Female
18 Years to 49 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00109512
NBI-56418-0501
Not Provided
Sponsor
Abbott
Not Provided
Study Director: Laura Williams, MD Abbott
Abbott
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP